Medicines

Find Medicines

Search 21,000+ medicines by brand, generic, indication, or drug class

Medicine Indications Drug Classes
    Showing all medicines (21591 total)

    Moxlocin XG

    Moxifloxacin Hydrochloride + Xanthan Gum
    Ophthalmic Solution 0.5%+0.4% Allopathic Ophthalmic antibacterial drugs

    Indications

    Conjunctivitis

    Indication detailsView
    This ophthalmic solution is indicated for the treatment of bacterial conjunctivitis caused by susceptible strains of the following organisms-

    Aerobic Gram-positive microorganisms: Corynebacterium species, Micrococcus luteus, Staphylococcus aureus, Staphylococcus epidermidis, Staphylococcus haemolyticus, Staphylococcus hominis, Staphylococcus warneri, Streptococcus pneumonia, Streptococcus viridans group.

    Aerobic Gram-negative microorganisms: Acinetobacter iwoffii, Haemophilus influenza, Haemophilus parainfluenzae.
    Therapeutic classView
    Ophthalmic antibacterial drugs
    PharmacologyView
    The antimicrobial action of Moxifloxacin results from inhibition of the topoisomerase II (DNA gyrase) and topoisomerase IV. DNA gyrase is an essential enzyme that is involved in the replication, transcription and repair of bacterial DNA. Topoisomerase IV is an enzyme known to play a key role in the partitioning of the chromosomal DNA during bacterial cell division.
    DosageView
    One drop in the affected eye(s) 2 times daily for 7 days.
    Side effectsView
    In 1-6% patients the most frequently reported ocular adverse events are eye irritation, pyrexia, conjunctivitis, decreased visual acuity, dry eye, ocular discomfort, ocular hyperemia, ocular pain, ocular pruritus, subconjunctival hemorrhage and tearing.
    PrecautionsView
    Prolonged use may result in overgrowth of non-susceptible organisms, including fungi with other anti-infective.
    InteractionsView
    Drug-drug interaction studies have not been conducted with Moxifloxacin Hydrochloride.
    Pregnancy & lactationView
    Moxifloxacin should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus as there are no adequate and well-documented studies in pregnant women. Moxifloxacin has not been measured in human milk, although it can be presumed to be excreted in human milk. Caution should be exercised when Moxifloxacin is administered to a breast feeding mother.
    Pediatric usageView
    Pediatric Use: The safety and effectiveness of Moxifloxacin in infants below four months of age was not proven. However, several clinical studies show that the drug may be used safely in children even younger than one month of age.

    Geriatric Use: No overall differences in safety and effectiveness have been observed between elderly and younger patients.
    Overdose effectsView
    There is practically no risk of adverse effects due to accidental ingestion, since a bottle of 5 ml eye drops solution contains only 25 mg Moxifloxacin that is much lower than recommended daily oral dose.
    StorageView
    Store in a cool and dry place away from light. Keep out of reach of children. Do not touch the dropper tip to surfaces since this may contaminate the solution. After one month of the first opening do not use the medicine of dropper.

    Moxquin

    Moxifloxacin Hydrochloride (Ophthalmic)
    Ophthalmic Solution 0.50% Allopathic Ophthalmic antibacterial drugs

    Indications

    Ocular infections

    Indication detailsView
    The ophthalmic solution is indicated for the treatment of bacterial conjunctivitis caused by susceptible strains of the following organisms:
    • Aerobic Gram-positive microorganisms: Corynebacterium species, Micrococcus luteus, Staphylococcus aureus, Staphylococcus epidermidis, Staphylococcus haemolyticus, Staphylococcus hominis, Staphylococcus warneri, Streptococcus pneumoniae, Streptococcus viridans group.
    • Aerobic Gram-negative microorganisms: Acinetobacterlwoffii, Haemophilusinfluenzae, Haemophilus parainfluenzae.
    • Other microorganisms: Chlamydia trachomatis.
    Therapeutic classView
    Ophthalmic antibacterial drugs
    PharmacologyView
    The antimicrobial action of Moxifloxacin results from inhibition of the topoisomerase II (DNA gyrase) and topoisomerase IV. DNA gyrase is an essential enzyme that is involved in the replication, transcription and repair of bacterial DNA. Topoisomerase IV is an enzyme known to play a key role in the partitioning of the chromosomal DNA during bacterial cell division.
    DosageView
    Eye Drops: One drop in the affected eye 3 times per day for 7 days.

    Eye Ointment: It should be applied thinly and evenly to the affected eye three times a day for the first two days and for the next five days apply two times a day or as advised by the registered physician.
    Side effectsView
    The most frequently reported ocular adverse events were conjunctivitis, decreased visual acuity, dry eye, keratitis, ocular discomfort, ocular hyperemia, ocular pain, ocular pruritus, subconjunctival hemorrhage, and tearing. These events occurred in approximately 1-6% of patients. Nonocular adverse events reported at a rate of 1-4% were fever, increased cough, infection, otitis media, pharyngitis, rash, and rhinitis.
    ContraindicationsView
    Moxifloxacin Hydrochloride ophthalmic solution is contraindicated in patients with a history of hypersensitivity to Moxifloxacin, to other quinolones, or to any of the components in this medication.
    PrecautionsView
    As with other anti-infectives, prolonged use may result in overgrowth of nonsusceptible organisms, including fungi. If superinfection occurs, discontinue use and institute alternative therapy. Whenever clinical judgment dictates, the patient should be examined with the aid of magnification, such as slit lamp biomicroscopy, and, where appropriate, fluorescein staining. Patients should be advised not to wear contact lenses if they have signs and symptoms of bacterial conjunctivitis.
    InteractionsView
    Drug-drug interaction studies have not been conducted with Moxifloxacin Hydrochloride ophthalmic solution. In vitro studies indicate that Moxifloxacin does not inhibit CYP3A4, CYP2D6, CYP2C9, CYP2C19, or CYP1A2 indicating that Moxifloxacin is unlikely to alter the pharmacokinetics of drugs metabolized by these cytochrome P450 isozymes.
    Pregnancy & lactationView
    Since there are no adequate and well-controlled studies in pregnant women, Moxifloxacin Hydrochloride ophthalmic solution should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Moxifloxacin has not been measured in human milk, although it can be presumed to be excreted in human milk. Caution should be exercised when Moxifloxacin hydrochloride ophthalmic solution is administered to a nursing mother.
    StorageView
    Store bellow 25°C. Do not freeze. Store in cool and dry place, protected from light. Keep out of the reach of children. Do not touch dropper tip to any surface as this may contaminate this preparation. Do not use after one month of first opening.

    Moxquin

    Moxifloxacin Hydrochloride (Injection)
    IV Infusion 400 mg/250 ml Allopathic 4-Quinolone preparations

    Indications

    Skin and skin sructure infections

    Indication detailsView
    Moxifloxacin infusion is indicated for treating following infections in adults >18 years of age caused by designated, susceptible bacteria.
    • Acute Bacterial Sinusitis
    • Acute Bacterial Exacerbation of Chronic Bronchitis
    • Community Acquired Pneumonia
    • Skin and Skin Structure Infections: Uncomplicated and Complicated
    • Complicated Intra-Abdominal Infections.
    Therapeutic classView
    4-Quinolone preparations
    DosageView
    The dose of Moxifloxacin is 400 mg once daily. The duration of therapy depends on the type of infection as described in following:
    • Acute Bacterial Sinusitis: 400 mg once daily for 10 days.
    • Acute Bacterial Exacerbation of Chronic Bronchitis: 400 mg once daily for 5 days.
    • Community Acquired Pneumonia: 400 mg once daily for 7-14 days.
    • Uncomplicated Skin and Skin Structure Infections: 400 mg once daily for 7 days.
    • Complicated Skin and Skin Structure Infections: 400 mg once daily for 7-21 days.
    • Complicated Intra-Abdominal Infections: 400 mg once daily for 5-14 days.
    AdministrationView
    Moxifloxacin injection should be administered by intravenous infusion over a period of 60 minutes. Avoid bolus or rapid infusion.
    • Check the bag for minute leaks by squeezing the inner bag firmly. If leaks are found, or if seal is not intact, discard the solution.
    • Do not use if the solution is cloudy or a precipitate is present.
    • Do not use flexible bags in series connections.
    • Close flow control clamp of administration set.
    • Remove cover from port at bottom of bag.
    • Insert piercing pin of administration set into port with a twisting motion until the pin is firmly seated.
    • Suspend bag from hanger.
    • Squeeze and release drip chamber to establish proper fluid level in chamber during infusion of Moxifloxacin 400 mg intravenous infusion.
    • Open flow control clamp to expel air from set. Close clamp.
    • Regulate the rate of administration with flow control clamp.
    Side effectsView
    Treatment with Moxifloxacin (oral, IV or sequential therapy) may cause some side effects. Common (>1%) side effects include headache, nausea, vomiting, diarrhea, constipation, abdominal pain, dyspepsia, dizziness, pyrexia and insomnia etc. Less common (0.1 to <1%) side effects include neutropenia, palpitations, tachycardia, bradycardia, vertigo, tinnitus, dry mouth, gastritis, edema, fatigue, malaise, hyperglycemia, anorexia, hyperlipidemia, hypoglycemia, dehydration, back pain and arthralgia etc.
    ContraindicationsView
    Moxifloxacin is contraindicated in persons with known hypersensitivity to Moxifloxacin or other quinolone antibacterials .
    PrecautionsView
    Fluoroquinolones, including Moxifloxacin, are associated with an increased risk of tendinitis and tendon rupture in all ages. The risk of developing fluoroquinolone-associated tendinitis and tendon rupture is further increased in older patients usually over 60 years of age, in patients taking corticosteroid drugs, and in patients with kidney, heart or lung transplants. Fluoroquinolones have neuromuscular blocking activity and may exacerbate muscle weakness in persons with myasthenia gravis. Clostridium difficile-associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including Moxifloxacin, and may range in severity from mild diarrhea to fatal colitis.
    InteractionsView
    There are no data concerning an interaction of intravenous fluoroquinolones with oral antacids, sucralfate, multivitamins, didanosine, or metal cations. However, no fluoroquinolone should be co-administered with any solution containing multivalent cations, e.g., magnesium, through the same intravenous line. Quinolones, including Moxifloxacin, have been reported to enhance the anticoagulant effects of warfarin or its derivatives in the patient population. Although not observed with Moxifloxacin in predinical and clinical trials, the concomitant administration of a nonsteroidal anti-inflammatory drug with a quinolone may increase the risks of CNS stimulation and convulsions. There is limited information available on the potential for a pharmacodynamic interaction in humans between Moxifloxacin and other drugs that prolong the QTc interval of the electrocardiogram. Sotalol, a Class III antiarrhythmic, has been shown to further increase the QTc interval when combined with high doses of intravenous (IV) Moxifloxacin in dogs. Therefore, Moxifloxacin should be avoided with Class IA and Class III antiarrhythmics.
    Pregnancy & lactationView
    Pregnancy Category C. Because no adequate or well controlled studies have been conducted in pregnant women, Moxifloxacin should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Moxifloxacin is excreted in the breast milk of rats. Moxifloxacin may also be excreted in human milk. Because of the potential for serious adverse reactions in infants who are nursing from mothers taking Moxifloxacin, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.
    Pediatric usageView
    Pediatric patients: Safety and effectiveness in pediatric patients and adolescents less than 18 years of age have not been established.

    Geriatric patients: These patients are at increased risk for developing severe tendon disorders including tendon rupture when being treated with a fluoroquinolone such as Moxifloxacin. This risk is further increased in patients receiving concomitant corticosteroid therapy.
    StorageView
    Store below 25°C and protect from light. Avoid extreme heat and freezing. Keep out of reach of children.

    Moxquin

    Moxifloxacin Hydrochloride (Tablet)
    Tablet 400 mg Allopathic 4-Quinolone preparations

    Indications

    Acute bacterial sinusitis

    Indication detailsView
    Moxifloxacin is indicated for the treatment of acute bacterial sinusitis, acute exacerbation of chronic bronchitis, community acquired pneumonia, uncomplicated & complicated skin and skin structure infections, complicated intra-abdominal infections and pelvic inflammatory disease.
    Therapeutic classView
    4-Quinolone preparations
    PharmacologyView
    Moxifloxacin is a 4th generation synthetic broad spectrum, fluoroquinolone class of antibacterial drug. It has activity against a wide range of gram-positive, gram-negative, anaerobic and atypical bacteria including Mycoplasma pneumoniae. It acts by inhibiting topoisomerase II (DNA gyrase) and topoisomerase IV which are necessary for bacterial DNA replication, transcription & repair.
    DosageView
    Acute bacterial sinusitis: 400 mg once daily 7-10 days.
    Acute bacterial exacerbation of chronic bronchitis: 400 mg once daily 5-10 days.
    Community-acquired pneumonia: 400 mg once daily 7-14 days.
    Uncomplicated skin and skin structure infections: 400 mg once daily 7 days.
    Complicated skin and skin structure infections: 400 mg once daily 7-21 days.
    Complicated intra-abdominal infections: 400 mg once daily 5-14 days.
    Pelvic inflammatory disease: 400 mg once daily 14 days.
    Side effectsView
    Common side effects of Moxifloxacin include nausea, vomiting, diarrhea, headache and dizziness.
    ContraindicationsView
    It is contraindicated in patients with a history of hypersensitivity to Moxifloxacin or other quinolones.
    PrecautionsView
    Moxifloxacin may cause an increased risk of tendinitis and tendon rupture. It should be discontinued if pain or inflammation in a tendon occurs. It should not be used in patients with known prolongation of the QT interval, patients with uncorrected hypokalemia, and patients with receiving Class IA or Class III antiarrhythmic agents
    InteractionsView
    Moxifloxacin absorption is decreased when administered with antacids, sucralfate, multivitamins, and multivalent cations (e.g. iron or zinc). Moxifloxacin may enhance the risk of convulsions with NSAIDs and bleeding with warfarin. So concomitant use of Moxifloxacin with them should be avoided.
    Pregnancy & lactationView
    US FDA pregnancy category C. Moxifloxacin is not recommended during pregnancy & lactation.
    Pediatric usageView
    Renal or hepatic impaired patients: No dose adjustment is necessary for patients with renal or hepatic impairment.

    Pediatric patients: Safety and effectiveness of Moxifloxacin in pediatric patients and adolescent less than 18 years of age have not been established.
    StorageView
    Keep in a dry place, away from light and heat. Keep out of the reach of children.

    Moxquin D

    Moxifloxacin Hydrochloride + Dexamethasone
    Ophthalmic Solution 0.5%+0.1% Allopathic Ophthalmic Steroid preparations

    Indications

    Steroid-responsive inflammatory ocular conditions

    Indication detailsView
    Moxifloxacin & Dexamethasone eye drop is indicated in the treatment of eye infections caused by susceptible microorganisms and in the prevention of inflammation and bacterial infection that may occur after eye surgery.
    Therapeutic classView
    Ophthalmic Steroid preparations
    PharmacologyView
    This Eye Drops is a combination of a fourth generation fluoroquinolone Moxifloxacin and a potent corticosteroid Dexmethasone. Moxifloxacin controls infection by inhibitting the DNA gyrase & Topoisomerase IV. Dexamethasone effectively controls the inflammation by inhibiting the release inflammatory mediators.
    DosageView
    In the prevention of infection and post-surgical ocular inflammation: Instill 1 drop, 4 times a day, in the eye to be operated, from 1 day before surgery until 15 days after surgery.

    In patients undergoing cataract surgery: The day of surgery instill the medication immediately after eye surgery.

    In patients undergoing LASIK refractive surgery: On the day of surgery instill the medication at least 15 minutes after ocular surgery.

    In eye infections caused by susceptible microorganisms: Instill 1 drop, 4 times a day, for up to 7 days.
    Side effectsView
    Moxifloxacin: Conjunctivitis decreased visual acuity, dry eye, keratitis, Ocular discomfort, hyperemia, pain, Subconjunctival hemorrhage and tearing.

    Dexamethasone: Visual acuity & field defects, cataract formation, secondary ocular infection following suppression of host response & perforation of the globe.
    ContraindicationsView
    Hypersensitivity to quinolones. Epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, varicella & other viral diseases of cornea & conjunctiva. Mycobacterial infection of the eye. Fungal diseases of ocular structures. Glaucoma & diseases causing thinning of cornea or sclera.
    PrecautionsView
    For ophthalmic use only. The solution should not be injected under the conjunctiva, nor introduced directly into the anterior chamber of the eye. Prolonged use of steroids may result in ocular hypertension
    Pregnancy & lactationView
    There are no adequate and well-controlled studies in pregnant women. Moxifloxacin & Dexamethasone combination eye drops should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Caution is advised when Moxifloxacin & Dexamethasone combination eye drops is given to nursing women.
    Pediatric usageView
    Use in the elderly: No change in dosage is required when the product is administered in elderly patients.

    Use in Children: The efficacy and safety of Moxifloxacin & Dexamethasone combination eye drops in pediatric patients have not been established.
    Overdose effectsView
    No information is available on overdosage with this product in humans.
    StorageView
    Store in a cool place, below 30°C, protected from light. Once the container is opened the contents must be used within 28 days and may be stored at room temperature up to 30°C. Discard after the 28 days. Keep out of reach of children.

    Moxquin XG

    Moxifloxacin Hydrochloride + Xanthan Gum
    Ophthalmic Solution 0.5%+0.4% Allopathic Ophthalmic antibacterial drugs

    Indications

    Conjunctivitis

    Indication detailsView
    This ophthalmic solution is indicated for the treatment of bacterial conjunctivitis caused by susceptible strains of the following organisms-

    Aerobic Gram-positive microorganisms: Corynebacterium species, Micrococcus luteus, Staphylococcus aureus, Staphylococcus epidermidis, Staphylococcus haemolyticus, Staphylococcus hominis, Staphylococcus warneri, Streptococcus pneumonia, Streptococcus viridans group.

    Aerobic Gram-negative microorganisms: Acinetobacter iwoffii, Haemophilus influenza, Haemophilus parainfluenzae.
    Therapeutic classView
    Ophthalmic antibacterial drugs
    PharmacologyView
    The antimicrobial action of Moxifloxacin results from inhibition of the topoisomerase II (DNA gyrase) and topoisomerase IV. DNA gyrase is an essential enzyme that is involved in the replication, transcription and repair of bacterial DNA. Topoisomerase IV is an enzyme known to play a key role in the partitioning of the chromosomal DNA during bacterial cell division.
    DosageView
    One drop in the affected eye(s) 2 times daily for 7 days.
    Side effectsView
    In 1-6% patients the most frequently reported ocular adverse events are eye irritation, pyrexia, conjunctivitis, decreased visual acuity, dry eye, ocular discomfort, ocular hyperemia, ocular pain, ocular pruritus, subconjunctival hemorrhage and tearing.
    PrecautionsView
    Prolonged use may result in overgrowth of non-susceptible organisms, including fungi with other anti-infective.
    InteractionsView
    Drug-drug interaction studies have not been conducted with Moxifloxacin Hydrochloride.
    Pregnancy & lactationView
    Moxifloxacin should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus as there are no adequate and well-documented studies in pregnant women. Moxifloxacin has not been measured in human milk, although it can be presumed to be excreted in human milk. Caution should be exercised when Moxifloxacin is administered to a breast feeding mother.
    Pediatric usageView
    Pediatric Use: The safety and effectiveness of Moxifloxacin in infants below four months of age was not proven. However, several clinical studies show that the drug may be used safely in children even younger than one month of age.

    Geriatric Use: No overall differences in safety and effectiveness have been observed between elderly and younger patients.
    Overdose effectsView
    There is practically no risk of adverse effects due to accidental ingestion, since a bottle of 5 ml eye drops solution contains only 25 mg Moxifloxacin that is much lower than recommended daily oral dose.
    StorageView
    Store in a cool and dry place away from light. Keep out of reach of children. Do not touch the dropper tip to surfaces since this may contaminate the solution. After one month of the first opening do not use the medicine of dropper.

    Mtrex

    Methotrexate
    Tablet 2.5 mg Allopathic Immunosuppressant

    Indications

    Vasculitis

    Indication detailsView
    Neoplastic Diseases: Methotrexate is indicated in the treatment of gestational choriocarcinoma, chorioadenoma destruens and hydatidiform mole. Methotrexate is used in maintenance therapy in combination with other chemotherapeutic agents. Methotrexate is used alone or in combination with other anticancer agents in the treatment of breast  cancer, epidermoid cancers of the head and neck, advanced mycosis fungoides (cutaneous T cell lymphoma), and lung cancer, particularly squamous cell and small cell types. Methotrexate is also used in combination with other chemotherapeutic agents in the treatment of advanced stage non-Hodgkin's lymphomas.

    Psoriasis: Methotrexate is indicated in the symptomatic control of severe, recalcitrant, disabling psoriasis that is not adequately responsive to other forms of therapy, but only when the diagnosis has been established, as by biopsy and/or after dermatologic consultation. It is important to ensure that a psoriasis “flare” is not due to an undiagnosed concomitant disease affecting immune responses.

    Rheumatoid Arthritis Including Polyarticular-Course Juvenile Rheumatoid Arthritis: Methotrexate is indicated in the management of selected adults with severe, active, rheumatoid arthritis (ACR criteria), or children with active polyarticular course juvenile rheumatoid arthritis, who have had an insufficient therapeutic response to, or are intolerant of, an adequate trial of first-line therapy including full dose non-steroidal anti-inflammatory agents (NSAIDs).

    Aspirin, NSAIDs, and/or low dose steroids may be continued, although the possibility of increased toxicity with concomitant use of NSAIDs including salicylates has not been fully explored. Steroids may be reduced gradually in patients who respond to methotrexate. Combined use of methotrexate with gold, penicillamine, hydroxychloroquine, sulfasalazine, or cytotoxic agents, has not been studied and may increase the incidence of adverse effects. Rest and physiotherapy as indicated should be continued.
    Therapeutic classView
    Antidote preparations, Immunosuppressant
    PharmacologyView
    Methotrexate inhibits dihydrofolic acid reductase. Dihydrofolates must be reduced to tetrahydrofolates by this enzyme before they can be utilized as carriers of one-carbon groups in the synthesis of p.r.n. nucleotides and thymidylate. Therefore, methotrexate interferes with DNA synthesis, repair, and cellular replication. Actively proliferating tissues such as malignant cells, bone marrow, fetal cells, buccal and intestinal mucosa, and cells of the urinary bladder are in general more sensitive to this effect of methotrexate. When cellular proliferation in malignant tissues is greater than in most normal tissues, methotrexate may impair malignant growth without irreversible damage to normal tissues
    DosageView
    Oral-
    • Choriocarcinoma: 15-30 mg daily for 5 days, repeat after an interval of ≥1 wk for 3-5 courses.
    • Acute lymphoblastic leukaemia: Maintenance: 15 mg/m2 once or twice wkly, with other agents.
    • Burkitt's lymphoma: 10-25 mg daily for 4-8 days, repeated after 7-10 days.
    • Psoriasis: 10-25 mg wkly as a single dose, adjust subsequent doses based on response.
    • Rheumatoid arthritis: 7.5 mg once wkly, adjust by response. Not more than 20 mg/wk.
    • Mycosis fungoides: 2.5-10 mg daily to induce remission.
    • Crohn's disease: 12.5-22.5 mg once wkly for up to 1 yr.
    Parenteral-
    • Psoriasis: 10-25 mg wkly as a single dose. Adjust subsequent doses based on response. May be given via IV/IM admin.
    Intramuscular-
    • Choriocarcinoma: 15-30 mg daily for 5 days. Repeat after at least 1 wk for 3-5 courses. Alternatively, 0.25-1 mg/kg (max: 60 mg) every 48 hr for 4 doses followed by folinic acid rescue, repeat at intervals of 7 days for 4 or more courses.
    • Mycosis fungoides: 50 mg wkly as a single dose or 2 divided doses.
    • Acute lymphoblastic leukaemia: Maintenance: 15 mg/m2 once or twice wkly, with other agents.
    • Crohn's disease: 25 mg once wkly for 16 wk. Maintenance: 15 mg wkly.
    Intrathecal-
    • Meningeal leukaemia: 12 mg/m2 (max 15 mg) once wkly for 2-3 wk, then once mthly. Alternatively, 200-500 mcg/kg every 2-5 day until CSF cell count is normalised.
    Intravenous-
    • Osteosarcoma: Initial recommended dose: 12 g/m2 as a 4-hr infusion, followed by folinic acid, as part of combined therapy. May increase dose to 15 g/m2 in subsequent treatments if initial dosage is insufficient to achieve peak serum methotrexate levels of 454 mcg/mL at the end of the infusion. Methotrexate infusion is administered on postoperative wk 4, 5, 6, 7, 11, 12, 15, 16, 29, 30, 44 and 45; in combination with other chemotherapy agents. Folinic acid can be given orally, IM or IV inj starting 24 hr after the beginning of the methotrexate infusion. Give via parenteral routes If patient experiences GI toxicity (e.g., nausea, vomiting). Usual dosage of folinic acid: 15 mg every 6 hr for a total of 60 hr or a total of 10 doses.
    • Breast cancer: 10-60 mg/m2 often with cyclophosphamide and fluorouracil.
    • Advanced lymphosarcoma: Up to 30 mg/kg, followed by folinic acid rescue.
    • Acute lymphoblastic leukaemia: Maintenance: 2.5 mg/kg every 14 days.
    AdministrationView
    Should be taken on an empty stomach. Best taken on an empty stomach. May be taken with meals to reduce GI discomfort. Avoid taking with milk-rich products.
    Side effectsView
    Ulceration of the mouth and GI disturbances (e.g. stomatitis and diarrhoea), bone marrow depression, hepatotoxicity, renal failure, skin reactions, alopecia, ocular irritation, arachnoiditis in intrathecal use, megaloblastic anaemia, osteoporosis, precipitation of diabetes, arthralgias, necrosis of soft tissue and bone, anaphylaxis, impaired fertility.
    ContraindicationsView
    Severe renal or hepatic impairment, pre-existing profound bone marrow suppression in patients with psoriasis or rheumatoid arthritis, alcoholic liver disease, AIDS, pre-existing blood dyscrasias, pregnancy (in patients with psoriasis or rheumatoid arthritis), breast-feeding.
    PrecautionsView
    Hepatic or renal impairment, bone marrow depression, elderly, neonates. Ulcerative disorders of the GI tract. Monitor haematological, renal and hepatic function, and GI toxicity regularly.
    InteractionsView
    Decreased effectiveness with folic acid and its derivatives.
    Pregnancy & lactationView
    Pregnancy category X. Studies in animals or human beings have demonstrated fetal abnormalities or there is evidence of fetal risk based on human experience or both, and the risk of the use of the drug in pregnant women clearly outweighs any possible benefit. The drug is contraindicated in women who are or may become pregnant.
    Overdose effectsView
    Nausea, vomiting, alopecia, melena, and renal failure.
    ReconstitutionView
    Intramuscular: Dilute powder with D5W or normal saline to a concentration ≤25 mg/ml (20 mg and 50 mg vials) and 50 mg/ml (1 g vial).

    Intrathecal:     Reconstitute to 2.5-5 mg/ml with normal saline, D5W, lactated Ringer's, or Elliott's B solution. Use preservative-free preparations.

    Intravenous:     Dilute powder with D5W or normal saline to a concentration ≤25 mg/ml (20 mg and 50 mg vials) and 50 mg/ml (1 g vial).

    Parenteral:     Dilute powder with D5W or normal saline to a concentration ≤25 mg/ml (20 mg and 50 mg vials) and 50 mg/ml (1 g vial).
    StorageView
    Store at room temperature (15-25°C).

    Mtrex

    Methotrexate
    Injection 50 mg/2 ml Allopathic Immunosuppressant

    Indications

    Vasculitis

    Indication detailsView
    Neoplastic Diseases: Methotrexate is indicated in the treatment of gestational choriocarcinoma, chorioadenoma destruens and hydatidiform mole. Methotrexate is used in maintenance therapy in combination with other chemotherapeutic agents. Methotrexate is used alone or in combination with other anticancer agents in the treatment of breast  cancer, epidermoid cancers of the head and neck, advanced mycosis fungoides (cutaneous T cell lymphoma), and lung cancer, particularly squamous cell and small cell types. Methotrexate is also used in combination with other chemotherapeutic agents in the treatment of advanced stage non-Hodgkin's lymphomas.

    Psoriasis: Methotrexate is indicated in the symptomatic control of severe, recalcitrant, disabling psoriasis that is not adequately responsive to other forms of therapy, but only when the diagnosis has been established, as by biopsy and/or after dermatologic consultation. It is important to ensure that a psoriasis “flare” is not due to an undiagnosed concomitant disease affecting immune responses.

    Rheumatoid Arthritis Including Polyarticular-Course Juvenile Rheumatoid Arthritis: Methotrexate is indicated in the management of selected adults with severe, active, rheumatoid arthritis (ACR criteria), or children with active polyarticular course juvenile rheumatoid arthritis, who have had an insufficient therapeutic response to, or are intolerant of, an adequate trial of first-line therapy including full dose non-steroidal anti-inflammatory agents (NSAIDs).

    Aspirin, NSAIDs, and/or low dose steroids may be continued, although the possibility of increased toxicity with concomitant use of NSAIDs including salicylates has not been fully explored. Steroids may be reduced gradually in patients who respond to methotrexate. Combined use of methotrexate with gold, penicillamine, hydroxychloroquine, sulfasalazine, or cytotoxic agents, has not been studied and may increase the incidence of adverse effects. Rest and physiotherapy as indicated should be continued.
    Therapeutic classView
    Antidote preparations, Immunosuppressant
    PharmacologyView
    Methotrexate inhibits dihydrofolic acid reductase. Dihydrofolates must be reduced to tetrahydrofolates by this enzyme before they can be utilized as carriers of one-carbon groups in the synthesis of p.r.n. nucleotides and thymidylate. Therefore, methotrexate interferes with DNA synthesis, repair, and cellular replication. Actively proliferating tissues such as malignant cells, bone marrow, fetal cells, buccal and intestinal mucosa, and cells of the urinary bladder are in general more sensitive to this effect of methotrexate. When cellular proliferation in malignant tissues is greater than in most normal tissues, methotrexate may impair malignant growth without irreversible damage to normal tissues
    DosageView
    Oral-
    • Choriocarcinoma: 15-30 mg daily for 5 days, repeat after an interval of ≥1 wk for 3-5 courses.
    • Acute lymphoblastic leukaemia: Maintenance: 15 mg/m2 once or twice wkly, with other agents.
    • Burkitt's lymphoma: 10-25 mg daily for 4-8 days, repeated after 7-10 days.
    • Psoriasis: 10-25 mg wkly as a single dose, adjust subsequent doses based on response.
    • Rheumatoid arthritis: 7.5 mg once wkly, adjust by response. Not more than 20 mg/wk.
    • Mycosis fungoides: 2.5-10 mg daily to induce remission.
    • Crohn's disease: 12.5-22.5 mg once wkly for up to 1 yr.
    Parenteral-
    • Psoriasis: 10-25 mg wkly as a single dose. Adjust subsequent doses based on response. May be given via IV/IM admin.
    Intramuscular-
    • Choriocarcinoma: 15-30 mg daily for 5 days. Repeat after at least 1 wk for 3-5 courses. Alternatively, 0.25-1 mg/kg (max: 60 mg) every 48 hr for 4 doses followed by folinic acid rescue, repeat at intervals of 7 days for 4 or more courses.
    • Mycosis fungoides: 50 mg wkly as a single dose or 2 divided doses.
    • Acute lymphoblastic leukaemia: Maintenance: 15 mg/m2 once or twice wkly, with other agents.
    • Crohn's disease: 25 mg once wkly for 16 wk. Maintenance: 15 mg wkly.
    Intrathecal-
    • Meningeal leukaemia: 12 mg/m2 (max 15 mg) once wkly for 2-3 wk, then once mthly. Alternatively, 200-500 mcg/kg every 2-5 day until CSF cell count is normalised.
    Intravenous-
    • Osteosarcoma: Initial recommended dose: 12 g/m2 as a 4-hr infusion, followed by folinic acid, as part of combined therapy. May increase dose to 15 g/m2 in subsequent treatments if initial dosage is insufficient to achieve peak serum methotrexate levels of 454 mcg/mL at the end of the infusion. Methotrexate infusion is administered on postoperative wk 4, 5, 6, 7, 11, 12, 15, 16, 29, 30, 44 and 45; in combination with other chemotherapy agents. Folinic acid can be given orally, IM or IV inj starting 24 hr after the beginning of the methotrexate infusion. Give via parenteral routes If patient experiences GI toxicity (e.g., nausea, vomiting). Usual dosage of folinic acid: 15 mg every 6 hr for a total of 60 hr or a total of 10 doses.
    • Breast cancer: 10-60 mg/m2 often with cyclophosphamide and fluorouracil.
    • Advanced lymphosarcoma: Up to 30 mg/kg, followed by folinic acid rescue.
    • Acute lymphoblastic leukaemia: Maintenance: 2.5 mg/kg every 14 days.
    AdministrationView
    Should be taken on an empty stomach. Best taken on an empty stomach. May be taken with meals to reduce GI discomfort. Avoid taking with milk-rich products.
    Side effectsView
    Ulceration of the mouth and GI disturbances (e.g. stomatitis and diarrhoea), bone marrow depression, hepatotoxicity, renal failure, skin reactions, alopecia, ocular irritation, arachnoiditis in intrathecal use, megaloblastic anaemia, osteoporosis, precipitation of diabetes, arthralgias, necrosis of soft tissue and bone, anaphylaxis, impaired fertility.
    ContraindicationsView
    Severe renal or hepatic impairment, pre-existing profound bone marrow suppression in patients with psoriasis or rheumatoid arthritis, alcoholic liver disease, AIDS, pre-existing blood dyscrasias, pregnancy (in patients with psoriasis or rheumatoid arthritis), breast-feeding.
    PrecautionsView
    Hepatic or renal impairment, bone marrow depression, elderly, neonates. Ulcerative disorders of the GI tract. Monitor haematological, renal and hepatic function, and GI toxicity regularly.
    InteractionsView
    Decreased effectiveness with folic acid and its derivatives.
    Pregnancy & lactationView
    Pregnancy category X. Studies in animals or human beings have demonstrated fetal abnormalities or there is evidence of fetal risk based on human experience or both, and the risk of the use of the drug in pregnant women clearly outweighs any possible benefit. The drug is contraindicated in women who are or may become pregnant.
    Overdose effectsView
    Nausea, vomiting, alopecia, melena, and renal failure.
    ReconstitutionView
    Intramuscular: Dilute powder with D5W or normal saline to a concentration ≤25 mg/ml (20 mg and 50 mg vials) and 50 mg/ml (1 g vial).

    Intrathecal:     Reconstitute to 2.5-5 mg/ml with normal saline, D5W, lactated Ringer's, or Elliott's B solution. Use preservative-free preparations.

    Intravenous:     Dilute powder with D5W or normal saline to a concentration ≤25 mg/ml (20 mg and 50 mg vials) and 50 mg/ml (1 g vial).

    Parenteral:     Dilute powder with D5W or normal saline to a concentration ≤25 mg/ml (20 mg and 50 mg vials) and 50 mg/ml (1 g vial).
    StorageView
    Store at room temperature (15-25°C).

    Mtrex

    Methotrexate
    Tablet 10 mg Allopathic Immunosuppressant

    Indications

    Vasculitis

    Indication detailsView
    Neoplastic Diseases: Methotrexate is indicated in the treatment of gestational choriocarcinoma, chorioadenoma destruens and hydatidiform mole. Methotrexate is used in maintenance therapy in combination with other chemotherapeutic agents. Methotrexate is used alone or in combination with other anticancer agents in the treatment of breast  cancer, epidermoid cancers of the head and neck, advanced mycosis fungoides (cutaneous T cell lymphoma), and lung cancer, particularly squamous cell and small cell types. Methotrexate is also used in combination with other chemotherapeutic agents in the treatment of advanced stage non-Hodgkin's lymphomas.

    Psoriasis: Methotrexate is indicated in the symptomatic control of severe, recalcitrant, disabling psoriasis that is not adequately responsive to other forms of therapy, but only when the diagnosis has been established, as by biopsy and/or after dermatologic consultation. It is important to ensure that a psoriasis “flare” is not due to an undiagnosed concomitant disease affecting immune responses.

    Rheumatoid Arthritis Including Polyarticular-Course Juvenile Rheumatoid Arthritis: Methotrexate is indicated in the management of selected adults with severe, active, rheumatoid arthritis (ACR criteria), or children with active polyarticular course juvenile rheumatoid arthritis, who have had an insufficient therapeutic response to, or are intolerant of, an adequate trial of first-line therapy including full dose non-steroidal anti-inflammatory agents (NSAIDs).

    Aspirin, NSAIDs, and/or low dose steroids may be continued, although the possibility of increased toxicity with concomitant use of NSAIDs including salicylates has not been fully explored. Steroids may be reduced gradually in patients who respond to methotrexate. Combined use of methotrexate with gold, penicillamine, hydroxychloroquine, sulfasalazine, or cytotoxic agents, has not been studied and may increase the incidence of adverse effects. Rest and physiotherapy as indicated should be continued.
    Therapeutic classView
    Antidote preparations, Immunosuppressant
    PharmacologyView
    Methotrexate inhibits dihydrofolic acid reductase. Dihydrofolates must be reduced to tetrahydrofolates by this enzyme before they can be utilized as carriers of one-carbon groups in the synthesis of p.r.n. nucleotides and thymidylate. Therefore, methotrexate interferes with DNA synthesis, repair, and cellular replication. Actively proliferating tissues such as malignant cells, bone marrow, fetal cells, buccal and intestinal mucosa, and cells of the urinary bladder are in general more sensitive to this effect of methotrexate. When cellular proliferation in malignant tissues is greater than in most normal tissues, methotrexate may impair malignant growth without irreversible damage to normal tissues
    DosageView
    Oral-
    • Choriocarcinoma: 15-30 mg daily for 5 days, repeat after an interval of ≥1 wk for 3-5 courses.
    • Acute lymphoblastic leukaemia: Maintenance: 15 mg/m2 once or twice wkly, with other agents.
    • Burkitt's lymphoma: 10-25 mg daily for 4-8 days, repeated after 7-10 days.
    • Psoriasis: 10-25 mg wkly as a single dose, adjust subsequent doses based on response.
    • Rheumatoid arthritis: 7.5 mg once wkly, adjust by response. Not more than 20 mg/wk.
    • Mycosis fungoides: 2.5-10 mg daily to induce remission.
    • Crohn's disease: 12.5-22.5 mg once wkly for up to 1 yr.
    Parenteral-
    • Psoriasis: 10-25 mg wkly as a single dose. Adjust subsequent doses based on response. May be given via IV/IM admin.
    Intramuscular-
    • Choriocarcinoma: 15-30 mg daily for 5 days. Repeat after at least 1 wk for 3-5 courses. Alternatively, 0.25-1 mg/kg (max: 60 mg) every 48 hr for 4 doses followed by folinic acid rescue, repeat at intervals of 7 days for 4 or more courses.
    • Mycosis fungoides: 50 mg wkly as a single dose or 2 divided doses.
    • Acute lymphoblastic leukaemia: Maintenance: 15 mg/m2 once or twice wkly, with other agents.
    • Crohn's disease: 25 mg once wkly for 16 wk. Maintenance: 15 mg wkly.
    Intrathecal-
    • Meningeal leukaemia: 12 mg/m2 (max 15 mg) once wkly for 2-3 wk, then once mthly. Alternatively, 200-500 mcg/kg every 2-5 day until CSF cell count is normalised.
    Intravenous-
    • Osteosarcoma: Initial recommended dose: 12 g/m2 as a 4-hr infusion, followed by folinic acid, as part of combined therapy. May increase dose to 15 g/m2 in subsequent treatments if initial dosage is insufficient to achieve peak serum methotrexate levels of 454 mcg/mL at the end of the infusion. Methotrexate infusion is administered on postoperative wk 4, 5, 6, 7, 11, 12, 15, 16, 29, 30, 44 and 45; in combination with other chemotherapy agents. Folinic acid can be given orally, IM or IV inj starting 24 hr after the beginning of the methotrexate infusion. Give via parenteral routes If patient experiences GI toxicity (e.g., nausea, vomiting). Usual dosage of folinic acid: 15 mg every 6 hr for a total of 60 hr or a total of 10 doses.
    • Breast cancer: 10-60 mg/m2 often with cyclophosphamide and fluorouracil.
    • Advanced lymphosarcoma: Up to 30 mg/kg, followed by folinic acid rescue.
    • Acute lymphoblastic leukaemia: Maintenance: 2.5 mg/kg every 14 days.
    AdministrationView
    Should be taken on an empty stomach. Best taken on an empty stomach. May be taken with meals to reduce GI discomfort. Avoid taking with milk-rich products.
    Side effectsView
    Ulceration of the mouth and GI disturbances (e.g. stomatitis and diarrhoea), bone marrow depression, hepatotoxicity, renal failure, skin reactions, alopecia, ocular irritation, arachnoiditis in intrathecal use, megaloblastic anaemia, osteoporosis, precipitation of diabetes, arthralgias, necrosis of soft tissue and bone, anaphylaxis, impaired fertility.
    ContraindicationsView
    Severe renal or hepatic impairment, pre-existing profound bone marrow suppression in patients with psoriasis or rheumatoid arthritis, alcoholic liver disease, AIDS, pre-existing blood dyscrasias, pregnancy (in patients with psoriasis or rheumatoid arthritis), breast-feeding.
    PrecautionsView
    Hepatic or renal impairment, bone marrow depression, elderly, neonates. Ulcerative disorders of the GI tract. Monitor haematological, renal and hepatic function, and GI toxicity regularly.
    InteractionsView
    Decreased effectiveness with folic acid and its derivatives.
    Pregnancy & lactationView
    Pregnancy category X. Studies in animals or human beings have demonstrated fetal abnormalities or there is evidence of fetal risk based on human experience or both, and the risk of the use of the drug in pregnant women clearly outweighs any possible benefit. The drug is contraindicated in women who are or may become pregnant.
    Overdose effectsView
    Nausea, vomiting, alopecia, melena, and renal failure.
    ReconstitutionView
    Intramuscular: Dilute powder with D5W or normal saline to a concentration ≤25 mg/ml (20 mg and 50 mg vials) and 50 mg/ml (1 g vial).

    Intrathecal:     Reconstitute to 2.5-5 mg/ml with normal saline, D5W, lactated Ringer's, or Elliott's B solution. Use preservative-free preparations.

    Intravenous:     Dilute powder with D5W or normal saline to a concentration ≤25 mg/ml (20 mg and 50 mg vials) and 50 mg/ml (1 g vial).

    Parenteral:     Dilute powder with D5W or normal saline to a concentration ≤25 mg/ml (20 mg and 50 mg vials) and 50 mg/ml (1 g vial).
    StorageView
    Store at room temperature (15-25°C).

    Mubrox

    Ambroxol Hydrochloride
    Pediatric Drops 6 mg/ml Allopathic Cough expectorants & mucolytics

    Indications

    Sore throat

    Indication detailsView
    This is indicated in-
    • Productive cough
    • Acute and chronic inflammatory disorders of upper and lower respiratory tracts associated with viscid mucus including acute and chronic bronchitis
    • Inflammatory disease of rhinopharyngeal tract (laryngitis, pharyngitis, sinusitis and rhinitis) associated with viscid mucus
    • Asthmatic bronchitis bronchial asthma with thick expectoration
    • Bronchiectasis
    • Chronic pneumonia etc.
    Therapeutic classView
    Cough expectorants & mucolytics
    PharmacologyView
    Ambroxol is the active metabolite of bromhexine and it has been proven that this metabolite possesses a greater bronchosecretolytic effect than bromhexine. It improves sputum rheology by hydrating mechanism leading to liquefaction of mucus in the lumen of respiratory tract, thus facilitating expectoration of mucus and reducing dyspnea. It stimulates production of phospholipids of surfactant by alveolar cells, thus contributing to the lowering of superficial tension in the alveoli. It also reduces bronchial hyperactivity. Ambroxol has anti inflammatory properties owing to the inhibitory effect on the production of cellular cytokines and arachidonic acid metabolites. In patients with COPD it traditionally improves airway patency.
    DosageView
    Average daily dose (preferably after meal):

    Pediatric Drops:
    • 0-6 months: 0.5 ml 2 times a day
    • 6-12 months: 1 ml 2 times a day
    • 1-2 years: 1.25 ml 2 times a day
    Syrup:
    • 2-5 years: 2.5 ml (1/2 teaspoonful) 2-3 times a day
    • 5-10 years: 5 ml (1 teaspoonful) 2-3 times a day
    • 10 years and adults: 10 ml (2 teaspoonful) 3 times a day.
    Sustained release capsule: Adult and children over 12 years old: 1 capsule once daily.
    Side effectsView
    Gastrointestinal side effects like epigastric pain, stomach overfill feeling may occur occasionally. Rarely allergic responses such as eruption, urticaria or angioneurotic edema have been reported.
    ContraindicationsView
    Contraindicated in known hypersensitivity to Ambroxol or Bromhexine.
    PrecautionsView
    Ambroxol should be given cautiously to patients with gastric and duodenal ulceration or convulsive disorders. Patients with hepatic and renal insufficiency should take it with caution.
    InteractionsView
    Ambroxol should not be taken simultaneously with antitussives (e.g.Codeine) because phlegm, which has been liquefied by Ambroxol might not be expectorated.
    Pregnancy & lactationView
    Teratogenic and fetal toxicity studies have shown no harmful effect of Ambroxol. However, it is advised not to use it in pregnancy, especially during the1st trimester. Safety during lactation has not been established yet.
    StorageView
    Protect from direct light exposure, Store in a dry place at a temperature not exceeding 30°C, Keep out of the reach of children.

    Mubrox

    Ambroxol Hydrochloride
    Syrup 15 mg/5 ml Allopathic Cough expectorants & mucolytics

    Indications

    Sore throat

    Indication detailsView
    This is indicated in-
    • Productive cough
    • Acute and chronic inflammatory disorders of upper and lower respiratory tracts associated with viscid mucus including acute and chronic bronchitis
    • Inflammatory disease of rhinopharyngeal tract (laryngitis, pharyngitis, sinusitis and rhinitis) associated with viscid mucus
    • Asthmatic bronchitis bronchial asthma with thick expectoration
    • Bronchiectasis
    • Chronic pneumonia etc.
    Therapeutic classView
    Cough expectorants & mucolytics
    PharmacologyView
    Ambroxol is the active metabolite of bromhexine and it has been proven that this metabolite possesses a greater bronchosecretolytic effect than bromhexine. It improves sputum rheology by hydrating mechanism leading to liquefaction of mucus in the lumen of respiratory tract, thus facilitating expectoration of mucus and reducing dyspnea. It stimulates production of phospholipids of surfactant by alveolar cells, thus contributing to the lowering of superficial tension in the alveoli. It also reduces bronchial hyperactivity. Ambroxol has anti inflammatory properties owing to the inhibitory effect on the production of cellular cytokines and arachidonic acid metabolites. In patients with COPD it traditionally improves airway patency.
    DosageView
    Average daily dose (preferably after meal):

    Pediatric Drops:
    • 0-6 months: 0.5 ml 2 times a day
    • 6-12 months: 1 ml 2 times a day
    • 1-2 years: 1.25 ml 2 times a day
    Syrup:
    • 2-5 years: 2.5 ml (1/2 teaspoonful) 2-3 times a day
    • 5-10 years: 5 ml (1 teaspoonful) 2-3 times a day
    • 10 years and adults: 10 ml (2 teaspoonful) 3 times a day.
    Sustained release capsule: Adult and children over 12 years old: 1 capsule once daily.
    Side effectsView
    Gastrointestinal side effects like epigastric pain, stomach overfill feeling may occur occasionally. Rarely allergic responses such as eruption, urticaria or angioneurotic edema have been reported.
    ContraindicationsView
    Contraindicated in known hypersensitivity to Ambroxol or Bromhexine.
    PrecautionsView
    Ambroxol should be given cautiously to patients with gastric and duodenal ulceration or convulsive disorders. Patients with hepatic and renal insufficiency should take it with caution.
    InteractionsView
    Ambroxol should not be taken simultaneously with antitussives (e.g.Codeine) because phlegm, which has been liquefied by Ambroxol might not be expectorated.
    Pregnancy & lactationView
    Teratogenic and fetal toxicity studies have shown no harmful effect of Ambroxol. However, it is advised not to use it in pregnancy, especially during the1st trimester. Safety during lactation has not been established yet.
    StorageView
    Protect from direct light exposure, Store in a dry place at a temperature not exceeding 30°C, Keep out of the reach of children.

    Mucin-R

    Ranitidine Hydrochloride
    Tablet 150 mg Allopathic H2 receptor antagonist

    Indications

    Zollinger-Ellison syndrome

    Indication detailsView
    Ranitidine is indicated in:
    • Treatment of active duodenal ulcer
    • Benign gastric ulcer
    • Treatment & prevention of ulcer associated with non-steroidal anti-inflammatory agent
    • Post operative stress ulcer.
    • Zollinger-Ellison Syndrome.
    • Gastroesophageal reflux disease (GERD).
    • Gastro-intestinal haemorrhage from stress ulcer in seriously ill patient.
    • Recurrent haemorrhage in patients with bleeding peptic ulcer.
    • Before general anesthesia in patient considered to be at risk of acid aspiration particulary obstetric patients.
    Therapeutic classView
    H2 receptor antagonist
    PharmacologyView
    Ranitidine competitively blocks histamine at H2-receptors of the gastric parietal cells which inhibits gastric acid secretion. It does not affect pepsin secretion, pentagastrin-stimulated intrinsic factor secretion or serum gastrin.
    DosageView

    Ranitidine Tablet & Syrup:

    Duodenal and gastric ulcer: The usual dosage is 150 mg twice daily taken in the morning and evening or 300 mg as a single daily dose at night for 4 to 8 weeks.

    Reflux oesophagitis: 150 mg twice daily or 300 mg at bed time for up to 8 weeks.

    Zollinger Ellison syndrome: 150 mg 3 times daily and increased if necessary up to 6 g daily in divided doses. Dosage should be continued as long as clinically indicated.

    Episodic dyspepsia: 150 mg twice daily or 300 mg at bed time for up to 6 weeks.

    Maintenance: 150 mg at night for preventing recurrences.

    Child (peptic ulcer): 2-4 mg/kg twice daily, maximum 300 mg daily.


    Ranitidine IV injection & IV Infusion:

    Ranitidine injection may be given either as a slow (over a period of at least two minutes) intravenous injection of 50 mg, after dilution to a volume of 20 ml per 50 mg dose, which may be repeated every six to eight hours; or as an intermittent intravenous infusion at a rate of 25 mg per hour for two hours; the infusion may be repeated at six to eight hour intervals; or as an intramuscular injection of 50 mg (2 ml) every six to eight hours. In the prophylaxis of haemorrhage from stress ulceration in seriously ill patients or the prophylaxis of recurrent haemorrhage in patients bleeding from peptic ulceration, parenteral administration may be continued until oral feeding commences.

    In the prophylaxis of upper gastrointestinal haemorrhage from stress ulceration in seriously ill patient sapriming dose of 50 mg as low as intravenous injection followed by a continuous intravenous infusion of 0.125-0.250 mg/kg/hour may be preferred. In patients considered to be at risk of developing aspiration syndrome Ranitidine injection 50 mg may be given intramuscularly or by slow intravenous injection 45 to 60 minutes before induction of general anaesthesia.

    Children: The recommended oral dose for the treatment of peptic ulcer in children is 2 mg/kg to 4 mg/kg twice daily to a maximum of 300 mg ranitidine per day. Safety and effectiveness of Ranitidine injection have not been established in case of children.
    Side effectsView
    Ranitidine is well tolerated and side effects are usually uncommon. Altered bowel habit, dizziness, rash, tiredness, reversible confusional states, headache, decreased blood counts, muscle or joint pain have rarely been reported.
    ContraindicationsView
    Patients hypersensitive to Ranitidine
    PrecautionsView
    Ranitidine should be given in reduced dosage to patients with impaired renal and hepatic function.
    InteractionsView
    Delayed absorption and increased peak serum concentration with propantheline bromide. Ranitidine minimally inhibits hepatic metabolism of coumarin anticoagulants, theophylline, diazepam and propanolol. May alter absorption of pH-dependent drugs (e.g. ketoconazole, midazolam, glipizide). May reduce bioavailability with antacids.
    Pregnancy & lactationView
    Pregnancy: Ranitidine crosses the placenta. But there is no evidence of impaired fertility or harm to the foetus due to Ranitidine. Like other drugs, Ranitidine should only be used during pregnancy if considered essential.

    Lactation: Ranitidine is excreted in human breast milk. Caution should be exercised when the drug is administered to a nursing mother.
    Pediatric usageView
    Use in elderly patients: In clinical trial the ulcer healing rates have been found similar in patients age 65 and over with those in younger patients. Additionally, there was no difference in the incidence of adverse effects.
    Overdose effectsView
    Ranitidine is very specific in action and accordingly no particular problems are expected following overdosage with the drug. Symptomatic and supportive therapy should be given as appropriate. If required, the drug may be removed from the plasma by haemodiaiysis.
    ReconstitutionView
    Slow IV inj: Ranitidine 50 mg diluted to a concentration ≤2.5 mg/mL (e.g. total of 20 mL) with NaCl 0.9% inj or dextrose 5% or 10%, lactated Ringer's, Na bicarbonate 5% soln.

    Intermittent slow IV infusion: Ranitidine 50 mg diluted to a concentration ≤0.5 mg/mL (e.g. total of 100 mL) of dextrose 5% inj or NaCl 0.9%, lactated Ringer's, Na bicarbonate 5% soln.

    Continuous IV infusion:     Ranitidine 150 mg diluted in 250 mL of dextrose 5% inj or NaCl 0.9%, lactated Ringer's, Na bicarbonate 5% soln.

    Patients with Zollinger-Ellison syndrome or other hypersecretory conditions: Ranitidine should be diluted to a concentration ≤2.5 mg/mL with dextrose 5% or NaCl 0.9%, lactated Ringer's, Na bicarbonate 5% soln.
    StorageView
    Store in a cool and dry place. protect from light.

    Mucobrox

    Ambroxol Hydrochloride
    Pediatric Drops 6 mg/ml Allopathic Cough expectorants & mucolytics

    Indications

    Sore throat

    Indication detailsView
    This is indicated in-
    • Productive cough
    • Acute and chronic inflammatory disorders of upper and lower respiratory tracts associated with viscid mucus including acute and chronic bronchitis
    • Inflammatory disease of rhinopharyngeal tract (laryngitis, pharyngitis, sinusitis and rhinitis) associated with viscid mucus
    • Asthmatic bronchitis bronchial asthma with thick expectoration
    • Bronchiectasis
    • Chronic pneumonia etc.
    Therapeutic classView
    Cough expectorants & mucolytics
    PharmacologyView
    Ambroxol is the active metabolite of bromhexine and it has been proven that this metabolite possesses a greater bronchosecretolytic effect than bromhexine. It improves sputum rheology by hydrating mechanism leading to liquefaction of mucus in the lumen of respiratory tract, thus facilitating expectoration of mucus and reducing dyspnea. It stimulates production of phospholipids of surfactant by alveolar cells, thus contributing to the lowering of superficial tension in the alveoli. It also reduces bronchial hyperactivity. Ambroxol has anti inflammatory properties owing to the inhibitory effect on the production of cellular cytokines and arachidonic acid metabolites. In patients with COPD it traditionally improves airway patency.
    DosageView
    Average daily dose (preferably after meal):

    Pediatric Drops:
    • 0-6 months: 0.5 ml 2 times a day
    • 6-12 months: 1 ml 2 times a day
    • 1-2 years: 1.25 ml 2 times a day
    Syrup:
    • 2-5 years: 2.5 ml (1/2 teaspoonful) 2-3 times a day
    • 5-10 years: 5 ml (1 teaspoonful) 2-3 times a day
    • 10 years and adults: 10 ml (2 teaspoonful) 3 times a day.
    Sustained release capsule: Adult and children over 12 years old: 1 capsule once daily.
    Side effectsView
    Gastrointestinal side effects like epigastric pain, stomach overfill feeling may occur occasionally. Rarely allergic responses such as eruption, urticaria or angioneurotic edema have been reported.
    ContraindicationsView
    Contraindicated in known hypersensitivity to Ambroxol or Bromhexine.
    PrecautionsView
    Ambroxol should be given cautiously to patients with gastric and duodenal ulceration or convulsive disorders. Patients with hepatic and renal insufficiency should take it with caution.
    InteractionsView
    Ambroxol should not be taken simultaneously with antitussives (e.g.Codeine) because phlegm, which has been liquefied by Ambroxol might not be expectorated.
    Pregnancy & lactationView
    Teratogenic and fetal toxicity studies have shown no harmful effect of Ambroxol. However, it is advised not to use it in pregnancy, especially during the1st trimester. Safety during lactation has not been established yet.
    StorageView
    Protect from direct light exposure, Store in a dry place at a temperature not exceeding 30°C, Keep out of the reach of children.

    Mucobrox

    Ambroxol Hydrochloride
    Syrup 15 mg/5 ml Allopathic Cough expectorants & mucolytics

    Indications

    Sore throat

    Indication detailsView
    This is indicated in-
    • Productive cough
    • Acute and chronic inflammatory disorders of upper and lower respiratory tracts associated with viscid mucus including acute and chronic bronchitis
    • Inflammatory disease of rhinopharyngeal tract (laryngitis, pharyngitis, sinusitis and rhinitis) associated with viscid mucus
    • Asthmatic bronchitis bronchial asthma with thick expectoration
    • Bronchiectasis
    • Chronic pneumonia etc.
    Therapeutic classView
    Cough expectorants & mucolytics
    PharmacologyView
    Ambroxol is the active metabolite of bromhexine and it has been proven that this metabolite possesses a greater bronchosecretolytic effect than bromhexine. It improves sputum rheology by hydrating mechanism leading to liquefaction of mucus in the lumen of respiratory tract, thus facilitating expectoration of mucus and reducing dyspnea. It stimulates production of phospholipids of surfactant by alveolar cells, thus contributing to the lowering of superficial tension in the alveoli. It also reduces bronchial hyperactivity. Ambroxol has anti inflammatory properties owing to the inhibitory effect on the production of cellular cytokines and arachidonic acid metabolites. In patients with COPD it traditionally improves airway patency.
    DosageView
    Average daily dose (preferably after meal):

    Pediatric Drops:
    • 0-6 months: 0.5 ml 2 times a day
    • 6-12 months: 1 ml 2 times a day
    • 1-2 years: 1.25 ml 2 times a day
    Syrup:
    • 2-5 years: 2.5 ml (1/2 teaspoonful) 2-3 times a day
    • 5-10 years: 5 ml (1 teaspoonful) 2-3 times a day
    • 10 years and adults: 10 ml (2 teaspoonful) 3 times a day.
    Sustained release capsule: Adult and children over 12 years old: 1 capsule once daily.
    Side effectsView
    Gastrointestinal side effects like epigastric pain, stomach overfill feeling may occur occasionally. Rarely allergic responses such as eruption, urticaria or angioneurotic edema have been reported.
    ContraindicationsView
    Contraindicated in known hypersensitivity to Ambroxol or Bromhexine.
    PrecautionsView
    Ambroxol should be given cautiously to patients with gastric and duodenal ulceration or convulsive disorders. Patients with hepatic and renal insufficiency should take it with caution.
    InteractionsView
    Ambroxol should not be taken simultaneously with antitussives (e.g.Codeine) because phlegm, which has been liquefied by Ambroxol might not be expectorated.
    Pregnancy & lactationView
    Teratogenic and fetal toxicity studies have shown no harmful effect of Ambroxol. However, it is advised not to use it in pregnancy, especially during the1st trimester. Safety during lactation has not been established yet.
    StorageView
    Protect from direct light exposure, Store in a dry place at a temperature not exceeding 30°C, Keep out of the reach of children.

    Mucoclean

    Ambroxol Hydrochloride
    Syrup 15 mg/5 ml Allopathic Cough expectorants & mucolytics

    Indications

    Sore throat

    Indication detailsView
    This is indicated in-
    • Productive cough
    • Acute and chronic inflammatory disorders of upper and lower respiratory tracts associated with viscid mucus including acute and chronic bronchitis
    • Inflammatory disease of rhinopharyngeal tract (laryngitis, pharyngitis, sinusitis and rhinitis) associated with viscid mucus
    • Asthmatic bronchitis bronchial asthma with thick expectoration
    • Bronchiectasis
    • Chronic pneumonia etc.
    Therapeutic classView
    Cough expectorants & mucolytics
    PharmacologyView
    Ambroxol is the active metabolite of bromhexine and it has been proven that this metabolite possesses a greater bronchosecretolytic effect than bromhexine. It improves sputum rheology by hydrating mechanism leading to liquefaction of mucus in the lumen of respiratory tract, thus facilitating expectoration of mucus and reducing dyspnea. It stimulates production of phospholipids of surfactant by alveolar cells, thus contributing to the lowering of superficial tension in the alveoli. It also reduces bronchial hyperactivity. Ambroxol has anti inflammatory properties owing to the inhibitory effect on the production of cellular cytokines and arachidonic acid metabolites. In patients with COPD it traditionally improves airway patency.
    DosageView
    Average daily dose (preferably after meal):

    Pediatric Drops:
    • 0-6 months: 0.5 ml 2 times a day
    • 6-12 months: 1 ml 2 times a day
    • 1-2 years: 1.25 ml 2 times a day
    Syrup:
    • 2-5 years: 2.5 ml (1/2 teaspoonful) 2-3 times a day
    • 5-10 years: 5 ml (1 teaspoonful) 2-3 times a day
    • 10 years and adults: 10 ml (2 teaspoonful) 3 times a day.
    Sustained release capsule: Adult and children over 12 years old: 1 capsule once daily.
    Side effectsView
    Gastrointestinal side effects like epigastric pain, stomach overfill feeling may occur occasionally. Rarely allergic responses such as eruption, urticaria or angioneurotic edema have been reported.
    ContraindicationsView
    Contraindicated in known hypersensitivity to Ambroxol or Bromhexine.
    PrecautionsView
    Ambroxol should be given cautiously to patients with gastric and duodenal ulceration or convulsive disorders. Patients with hepatic and renal insufficiency should take it with caution.
    InteractionsView
    Ambroxol should not be taken simultaneously with antitussives (e.g.Codeine) because phlegm, which has been liquefied by Ambroxol might not be expectorated.
    Pregnancy & lactationView
    Teratogenic and fetal toxicity studies have shown no harmful effect of Ambroxol. However, it is advised not to use it in pregnancy, especially during the1st trimester. Safety during lactation has not been established yet.
    StorageView
    Protect from direct light exposure, Store in a dry place at a temperature not exceeding 30°C, Keep out of the reach of children.

    Mucodil

    Bromhexine Hydrochloride
    Syrup 4 mg/5 ml Allopathic Cough expectorants & mucolytics

    Indications

    Bronchitis

    Indication detailsView
    Bromhexine is indicated in the treatment of respiratory tract disorders associated with productive cough. This include-
    • Tracheobronchitis
    • Bronchitis with emphysema
    • Bronchiectasis
    • Bronchitis with bronchospasm
    • Chronic inflammatory pulmonary conditions and
    • Pneumoconiosis.
    Therapeutic classView
    Cough expectorants & mucolytics
    PharmacologyView
    Bromhexine Hydrochloride is an oral mucolytic agent. It disrupts the structure of acid mucopolysaccharide fibres in mucoid sputum and produces less viscous mucus, which makes easier the expectoration. It is rapidly & completely absorbed from the gastrointestinal tract. It is widely distributed into the body tissues.
    DosageView
    The recommended doses for adults and children are stated below:
    • Adult & Children over 12 years: 10 ml (2 teaspoons) 3 times daily
    • Children 6-12 years: 5 ml (1 teaspoon) 3 times daily
    • Children 2-6 years: 2.5 ml (1/2 teaspoon) 3 times daily
    • Bromhexine Hydrochloride is not recommended for children under 2 years of age without advice.
    Side effectsView
    Gastrointestinal side effects may occur occasionally. A transient rise in serum aminotransferase values has been reported. Other reported side effects include-headache, vertigo (dizziness) and allergic reactions.
    ContraindicationsView
    It is contraindicated in known hypersensitivity to Bromhexine Hydrochloride or any of the ingredients of this product.
    PrecautionsView
    Since mucolytics may disrupt the gastric mucosa bromhexine should be used with care in patients with a history of peptic ulcer disease. Care is also advisable in asthmatic patients. Clearance of bromhexine and its metabolites may be reduced in patients with severe hepatic or renal impairment.
    InteractionsView
    There are no known significant interactions with other drugs.
    Pregnancy & lactationView
    Use in Pregnancy: Special care is recommended during pregnancy. The benefits of bromhexine must be assessed against possible effects on children.

    Use in Lactation: Bromhexine is expected to enter breast milk. Therefore it is not recommended that bromhexine be taken by lactating mothers.
    StorageView
    Keep in a dry place away from light and heat. Keep out of reach of children.

    Mucof

    Bromhexine Hydrochloride
    Syrup 4 mg/5 ml Allopathic Cough expectorants & mucolytics

    Indications

    Bronchitis

    Indication detailsView
    Bromhexine is indicated in the treatment of respiratory tract disorders associated with productive cough. This include-
    • Tracheobronchitis
    • Bronchitis with emphysema
    • Bronchiectasis
    • Bronchitis with bronchospasm
    • Chronic inflammatory pulmonary conditions and
    • Pneumoconiosis.
    Therapeutic classView
    Cough expectorants & mucolytics
    PharmacologyView
    Bromhexine Hydrochloride is an oral mucolytic agent. It disrupts the structure of acid mucopolysaccharide fibres in mucoid sputum and produces less viscous mucus, which makes easier the expectoration. It is rapidly & completely absorbed from the gastrointestinal tract. It is widely distributed into the body tissues.
    DosageView
    The recommended doses for adults and children are stated below:
    • Adult & Children over 12 years: 10 ml (2 teaspoons) 3 times daily
    • Children 6-12 years: 5 ml (1 teaspoon) 3 times daily
    • Children 2-6 years: 2.5 ml (1/2 teaspoon) 3 times daily
    • Bromhexine Hydrochloride is not recommended for children under 2 years of age without advice.
    Side effectsView
    Gastrointestinal side effects may occur occasionally. A transient rise in serum aminotransferase values has been reported. Other reported side effects include-headache, vertigo (dizziness) and allergic reactions.
    ContraindicationsView
    It is contraindicated in known hypersensitivity to Bromhexine Hydrochloride or any of the ingredients of this product.
    PrecautionsView
    Since mucolytics may disrupt the gastric mucosa bromhexine should be used with care in patients with a history of peptic ulcer disease. Care is also advisable in asthmatic patients. Clearance of bromhexine and its metabolites may be reduced in patients with severe hepatic or renal impairment.
    InteractionsView
    There are no known significant interactions with other drugs.
    Pregnancy & lactationView
    Use in Pregnancy: Special care is recommended during pregnancy. The benefits of bromhexine must be assessed against possible effects on children.

    Use in Lactation: Bromhexine is expected to enter breast milk. Therefore it is not recommended that bromhexine be taken by lactating mothers.
    StorageView
    Keep in a dry place away from light and heat. Keep out of reach of children.

    Mucogel

    Aluminium Hydroxide + Magnesium Hydroxide
    Oral Suspension (175 mg+225 mg)/5 ml Allopathic Antacids

    Indications

    Upper Gl bloating

    Indication detailsView
    Aluminium Hydroxide and Magnesium Hydroxide is indicated for Hyperacidity, peptic ulcer, gastritis, heartburn, sour stomach & dyspepsia.
    Therapeutic classView
    Antacids
    PharmacologyView
    This drug is well-balanced combination of essential non-systemic antacids which excel in efficacy and palatability. These are dependable antacid preparations without acid rebound, constipating or cathertic effects. Both the preparations provide symptomatic relief of hyperacidity associated with heartburn, acid ingestion or sour stomach.

    Aluminium hydroxide gel, a slow acting antacid and an adsorbent with prolonged effect, has high neutralizing power. Magnesium Hydroxide possesses a slow but sustained acid neutralizing property. Antacids of both tablet and suspension possess adsorbent property. They form a protecting coating over the ulcer surface facilitating its healing; thus protecting the sensitive mucosa of stomach and duodenum from further irritation.
    DosageView
    Tablet: Two tablets 1-3 hours after meal and at bed time or as directed by the physician.

    Suspension: 2 tea spoonful 1-3 hours after meal and at bed time or as directed by the physician.
    Side effectsView
    Long term use of any antacid results in alkaluria, which may predispose to nephrolithiasis by forming precipitation of calcium phosphate.
    ContraindicationsView
    This is contraindicated in hypophosphataemia. It is also contraindicated in alkalosis and hypermagnesaemia where abdominal distention may be due to partial or complete intestinal obstruction.
    PrecautionsView
    Antacids reduce the absorption of tetracycline when given concomitantly. These should not be used concomitantly
    InteractionsView
    This drug inhibits the absorption of following drugs: Azithromycin, cefpodoxime, ciprofloxacin, isoniazid, rifampicin, norfloxacin, ofloxacin, pivampicillin, tetracyclines, Gabapentin and phenytoin, Itraconazole, ketoconazole, Chloroquine, hydroxychloroquine and Phenothiazines.
    Pregnancy & lactationView
    It is advised to avoid antacid preparations in the first trimester of pregnancy.
    StorageView
    Keep below 30°C temperature, away from light & moisture. Keep out of the reach of children.

    Mucola

    Bromhexine Hydrochloride
    Syrup 4 mg/5 ml Allopathic Cough expectorants & mucolytics

    Indications

    Bronchitis

    Indication detailsView
    Bromhexine is indicated in the treatment of respiratory tract disorders associated with productive cough. This include-
    • Tracheobronchitis
    • Bronchitis with emphysema
    • Bronchiectasis
    • Bronchitis with bronchospasm
    • Chronic inflammatory pulmonary conditions and
    • Pneumoconiosis.
    Therapeutic classView
    Cough expectorants & mucolytics
    PharmacologyView
    Bromhexine Hydrochloride is an oral mucolytic agent. It disrupts the structure of acid mucopolysaccharide fibres in mucoid sputum and produces less viscous mucus, which makes easier the expectoration. It is rapidly & completely absorbed from the gastrointestinal tract. It is widely distributed into the body tissues.
    DosageView
    The recommended doses for adults and children are stated below:
    • Adult & Children over 12 years: 10 ml (2 teaspoons) 3 times daily
    • Children 6-12 years: 5 ml (1 teaspoon) 3 times daily
    • Children 2-6 years: 2.5 ml (1/2 teaspoon) 3 times daily
    • Bromhexine Hydrochloride is not recommended for children under 2 years of age without advice.
    Side effectsView
    Gastrointestinal side effects may occur occasionally. A transient rise in serum aminotransferase values has been reported. Other reported side effects include-headache, vertigo (dizziness) and allergic reactions.
    ContraindicationsView
    It is contraindicated in known hypersensitivity to Bromhexine Hydrochloride or any of the ingredients of this product.
    PrecautionsView
    Since mucolytics may disrupt the gastric mucosa bromhexine should be used with care in patients with a history of peptic ulcer disease. Care is also advisable in asthmatic patients. Clearance of bromhexine and its metabolites may be reduced in patients with severe hepatic or renal impairment.
    InteractionsView
    There are no known significant interactions with other drugs.
    Pregnancy & lactationView
    Use in Pregnancy: Special care is recommended during pregnancy. The benefits of bromhexine must be assessed against possible effects on children.

    Use in Lactation: Bromhexine is expected to enter breast milk. Therefore it is not recommended that bromhexine be taken by lactating mothers.
    StorageView
    Keep in a dry place away from light and heat. Keep out of reach of children.

    Mucolex

    Carbocisteine
    Syrup 125 mg/5 ml Allopathic Cough expectorants & mucolytics

    Indications

    Mucolytic

    Indication detailsView
    Carbocisteine is indicated for- Acute bronchitis, Chronic bronchitis, Bronchial asthma, Upper respiratory tract inflammation (pharyngitis, laryngitis), Cystic fibrosis Bronchiectasis, Pulmonary tuberculosis, Drainage in chronic sinusitis and pneumonia, Drainage in otitis media in children.
    Therapeutic classView
    Cough expectorants & mucolytics
    PharmacologyView
    Carbocisteine reduces goblet cell hyperplasia and therefore plays a role in the management of disorders characterised by abnormal mucous. Carbocisteine loosens thick sputum effectively by reducing its viscosity and thereby helps to expectorate that mucus more easily from the respiratory tract. The mucolytic action happens in several mechanisms. It breaks the disulphide bonds, which cross-link certain glycoprotein molecules in the mucus, the mucus produced under the influence of Carbocisteine has high sialomucin and low fucomucin content. This combined effect ultimately reduces the viscosity of the sputum and increases its volume.
    DosageView
    Adult: Initially, 2.25 g daily in divided doses, then 1.5 g daily in divided doses as condition improves.
    Child: 2-5 year: 62.5-125 mg 4 times daily; 6-12 year 250 mg tid.

    Should be taken with food.
    Side effectsView
    Gastrointestinal discomfort, nausea, diarrhoea, gastrointestinal bleeding, palpitation, dizziness, headache, heartburn and skin rash may occur.
    ContraindicationsView
    Contraindicated in active peptic ulceration and in patients with hypersensitivity to the drug.
    PrecautionsView
    No specific precaution is recommended but Carbocisteine should be used with caution in patients with a recent history of peptic ulcer and recurrent gastrointestinal bleeding.
    InteractionsView
    Neither hazardous nor therapeutically useful interactions have been reported.
    Pregnancy & lactationView
    There is no information on the use of Carbocisteine during lactation. While there are no reports of teratogenic effects, the manufacturers do not recommend the use of Carbocisteine in the first trimester.
    Overdose effectsView
    Symptoms: GI disturbance.
    Management: May perform gastric lavage, followed by observation.
    StorageView
    Store in a cool and dry place protected from light.